MorphoSys AG (MOR)
NASDAQ: MOR · IEX Real-Time Price · USD
18.10
-0.06 (-0.33%)
At close: Jul 2, 2024, 4:00 PM
18.04
-0.06 (-0.33%)
After-hours: Jul 2, 2024, 5:14 PM EDT
MorphoSys AG Revenue
In the year 2023, MorphoSys AG had annual revenue of $264.75M, a decrease of -10.56%.
Revenue (ttm)
$264.75M
Revenue Growth
+6.07%
P/S Ratio
10.30
Revenue / Employee
$505,255
Employees
524
Market Cap
2.73B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 264.75M | -31.28M | -10.56% |
Dec 31, 2022 | 296.03M | 91.92M | 45.04% |
Dec 31, 2021 | 204.10M | -195.53M | -48.93% |
Dec 31, 2020 | 399.63M | 319.01M | 395.67% |
Dec 31, 2019 | 80.62M | -7.24M | -8.24% |
Dec 31, 2018 | 87.86M | 7.71M | 9.62% |
Dec 31, 2017 | 80.15M | 27.80M | 53.11% |
Dec 31, 2016 | 52.35M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 4.78B |
Progyny | 1.11B |
ACADIA Pharmaceuticals | 813.81M |
Tandem Diabetes Care | 770.01M |
Azenta | 651.76M |
Inari Medical | 520.66M |
TG Therapeutics | 289.33M |
SpringWorks Therapeutics | 26.45M |
MOR News
- 12 days ago - MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders - Business Wire
- 12 days ago - MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders - Business Wire
- 12 days ago - Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG's Minority Shareholders - Accesswire
- 6 weeks ago - Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash - GlobeNewsWire
- 2 months ago - MorphoSys AG Reports First Quarter 2024 Financial Results - Business Wire
- 2 months ago - Morphosys says Novartis takeover progressing as planned for H1 2024 - Reuters
- 2 months ago - MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting - Accesswire
- 2 months ago - MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis - Accesswire